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Although allogeneic hematopoietic stem cell transplantation (allo-SCT) is performed as a curative option in
adult T cell leukemia-lymphoma (ATL) patients, its high transplantation-related mortality raises a serious
issue. The clinical features of infectious complications after transplantation are not well known. To analyze
the impact of infections after allo-SCT for ATL, we retrospectively compared infectious complications in 210
patients at 3 institutions in Nagasaki prefecture between 1997 and 2009. There were 91 patients with acute
myeloid leukemia (AML), 51 with acute lymphoblastic leukemia/lymphoblastic lymphoma (ALL/LBL), and 68
with ATL. No patient received ganciclovir or foscarvir as prophylaxis, and most patients received antifungal
prophylaxis with ﬂuconazole or itraconazole. The cumulative incidence of cytomegalovirus (CMV) infection at
3 years was 69.2% in ATL patients versus 54.4% in AML patients (P ¼ .0255). Cumulative infection-related
mortality was signiﬁcantly higher in ATL patients than in the 2 other groups (ATL versus AML, P ¼ .0496;
ATL versus ALL/LBL, P ¼ .0075), and most death-causing pathogens were bacteria and fungus. The appearance
of CMV infection was negatively associated with infectious mortality in ATL patients, but the P value for this
association was near the borderline of signiﬁcance (P ¼ .0569). In multivariate analysis, transplantation using
unrelated bone marrow and episodes of CMV infection were associated with worse overall survival in ATL
patients, but were not in either AML or ALL/LBL patients. Collectively, the impact of infectious complications
after transplantation in ATL patients was different from that in AML and ALL/LBL patients, suggesting that
a more intensive strategy for infection control in ATL patients is required to reduce infectious mortality.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION
Adult T cell leukemia-lymphoma (ATL) is a peripheral T
cell neoplasm caused by human T cell lymphotropic virus
type I (HTLV-I) [1-4]. The clinical features of ATL are
heterogeneous and are characterized by various degrees
of lymphadenopathy, abnormal lymphocytosis, hep-
atosplenomegaly, skin lesions, and hypercalcemia dividing
the disease into 4 subtypes: acute, lymphoma, chronic, and
smoldering [5]. Over the past decade, allogeneic hemato-
poietic stem cell transplantation (allo-SCT) was performed in
young patients with aggressive ATL (acute, lymphoma,
unfavorable chronic type) in Japan because aggressive ATL
shows resistance to a variety of cytotoxic agents and hasdgments on page 614.
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13.01.011a poor outcome [6,7]. Several reports demonstrated that allo-
SCT provided apparent long-term remission in some
patients, along with the graft-versus-ATL effect [8-17].
However, transplantation-related mortality was higher than
that observed for acute leukemia (acute myeloid leukemia
[AML] and acute lymphoblastic leukemia/lymphoblastic
lymphoma [ALL/LBL]), especially within 6months of allo-SCT
[10,14].
In general, ATL patients are susceptible to various
opportunistic infections, including Pneumocystis jirovecii
pneumonia (PJP), invasive fungal infections, and herpes virus
diseases because of defective cellular immunity. Suzumiya
et al. reported that cytomegalovirus (CMV) was involved in
35 of 47 autopsied cases of ATL and that CMV pneumoniawas
a signiﬁcant cause of death [18]. Furthermore, it has been
reported that development of PJP, invasive fungal infection,
and herpes virus disease are more frequent in patients with
ATL [19-22]. Collectively, infectious complications in patients
with ATL may be different from those in patients with acute
leukemia or malignant lymphoma, during allo-SCT. Recently,Transplantation.
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infectious mortality was a main cause of transplantation-
related mortality after transplantation for ATL [14].
However, there are no differences in prophylaxis and treat-
ment for infection between ATL and other hematological
diseases during the allo-SCT procedure. It remains unclear
whether the current strategy for infection is sufﬁcient or not
for post-transplant patients with ATL because of the lack of
detailed information for infectious complications after allo-
SCT in these patients.
In the present report, we retrospectively analyzed 210
post-transplant patients with ATL, AML, or ALL/LBL to clarify
differences in the clinical features of infectious complications
after allo-SCT for patients with ATL.
PATIENTS AND METHODS
Patient Population
In this study, adult patients aged 16 years or older who received allo-SCT
at 3 hospitals in Nagasaki prefecture with the diagnosis of AML, ALL/LBL, or
ATL were included. These patients underwent allo-SCT between September
1997 and December 2009. Of 228 patients whose data were available, 18
were excluded because of death without neutrophil engraftment. The
remaining 210 patients were included in the analysis. This study was
approved by the Ethical Committees of the participating hospitals.
Deﬁnition of Clinical Endpoints and Responses
Neutrophil engraftment was deﬁned by the recovery of an absolute
neutrophil count of at least 0.5  109/L for 3 consecutive points; platelet
recovery was deﬁned by the recovery of a count of at least 500  109/L
without transfusion support. Diagnosis and clinical grading of acute and
chronic graft-versus-host diseases (aGVHD and cGVHD) were performed
according to established criteria [23,24].
For ATL patients, response to treatment was divided into 4 categories:
complete remission (CR), partial remission (PR), stable disease, and
progressive disease. Responses were deﬁned as follows: CR, disappearance
of all disease; PR,  50% reduction in measurable disease; stable disease,
failure to attain CR, PR, and no progressive disease; progressive disease, any
new lesions or lesions with proliferation (increases in the size and number
of abnormal cells). For acute leukemia patients, CR was deﬁned as the
presence of all of the following: fewer than 5% blasts in bone marrow,
no leukemia blasts in peripheral blood, recovery of peripheral
neutrophil counts to more than 1.0 109/L, and platelet counts to more than
100  109/L, and no evidence of extramedullary leukemia.
Prophylaxis of Infection, and Monitoring and Preemptive Therapy for
CMV diseases
During the allo-SCT procedure, each patient was treated in a reverse
isolation room, which was ventilated with a high-efﬁciency particulate air
ﬁltration system. As prophylaxis of fungal infection, itraconazole (200 mg/
day) was administered to most patients from the start of conditioning
[25,26]. In the cases of itraconasole intolerance because of its adverse effects,
in principle, ﬂuconazole (100 mg/day) was administered before the year of
2004, and micafungin (50 mg/day) was used after 2005 when micafungin
became available for the prophylaxis of fungal infection after allo-SCT in
Japan. If these drugs also could not be tolerated, either amphotericin B or
voriconazole was administrated in accordance with the institutional
strategy. Prophylaxis against PJP was performed primarily with oral
trimethoprim-sulfamethoxazole [25]. All patients received prophylactic
antibodies (ceftazidime or ciproﬂoxacin) after absolute neutrophil counts
had become less than 0.5 109/L [25,27]. Acyclovir (1000 mg/day) was used
for the prevention of diseases by the herpes simplex virus and varicella-
zoster virus until day 100 after transplantation [25,28] regardless of sero-
positivity. After the recovery of neutrophils, CMV pp65 antigen in peripheral
blood was monitored weekly through day 100 after transplantation to
detect CMV antigenemia [29]. The CMV antigenemia test was considered
positive if at least one positive-stained cell per 5.0  104 cells was detected
on the slides. Preemptive therapy was initiated when CMV antigenemia
became positive. In most cases, ganciclovir (GCV) was administrated at an
induction dose of 5 mg/kg intravenously every 12 hours as preemptive
therapy [30,31]. After antigenemia had been eliminated, GCV was either
discontinued immediately or continued for a short time at a maintenance
dose, in accordance with the institutional strategy. Based on the high
positivity of CMV antibody among the Japanese population [32,33], the
evaluation of CMV-serostatus before transplantation was depended on the
institutional strategy. Instead, for prophylaxis of CMV, all patients receivedirradiated blood products, which were depleted of leukocytes by ﬁlters [34].
No patient was transfused with CMV-seronegative blood components.
Fungal Infections
Invasive fungal infections were divided into candidemia, invasive
aspergillosis, and apparent organ damage by other fungi or molds [35].
Invasive aspergillosis was deﬁned as possible (based on clinical signs and
symptoms plus a compatible chest computed tomography scan or X-ray),
probable (based on clinical signs and symptoms, compatible imaging test
results, plus a positive respiratory tract culture for Aspergillus spp. or positive
galactomannan assay), and deﬁnite (based on histology for an invasive mold
infection by Aspergillus) infections. Candida infection was deﬁned by the
positive results of fungal cultures in blood or urine samples, or by evidence
of infectious lesions in any organ system demonstrated by radiographic or
histological evaluation.
CMV Infection and CMV Disease
Diagnosis of CMV infection and CMV disease was made based on
previously described criteria [36]. In brief, CMV disease was deﬁned by the
presence of clinical signs and/or symptoms of end-organ disease combined
with the detection of CMV infection in a biopsy specimen or bron-
choalveolar lavage ﬂuid in case of pneumonia. CMV infectionwas deﬁned as
the isolation of a virus or detection of viral protein or nucleic acids in any
body ﬂuid or tissue specimen. CMV infection included both CMV anti-
genemia and CMV disease.
Viral Infections Other Than CMV
Patients who were culture- or polymerase chain reaction (PCR)-positive
for adenovirus with corresponding clinical signs and symptoms were
considered tohaveanadenovirus infection involving those sites [37]. BKvirus
infection was deﬁned as hemorrhagic cystitis with positive PCR results in
urine samples [38], and for human herpes virus-6 (HHV-6) infection, detec-
tion of the virus genome by PCR from blood and/or cerebrospinal ﬂuid [39].
Statistical Analysis
The KaplaneMeier method was used to estimate overall survival (OS)
after allo-SCT. The 95% conﬁdence interval of 3-year OS was calculated. To
illustrate the effects of cGVHD on OS, OS was measured from a predeﬁned
landmark time of 100 days after allo-SCT when analyzing the effect of this
factor. Probabilities between subgroupswere compared bymeans of the log-
rank test. Cumulative incidences of infectious complications and infection-
related death were calculated using Gray’s method, considering deaths
related to relapse or other complications than infection as a competing risk.
Furthermore, simultaneous effects of prognostic factors on OS were
analyzed using multivariate regression analysis based on the Cox’s propor-
tional hazards model and linear logistic model, respectively. Variables
considered were age of the patient at transplantation, sex of the patient,
donor type, disease status at conditioning, and the t(9;22) chromosome
abnormality or others for ALL/LBL, cytogenetic risk group deﬁned by the
Medical Research Council group [40,41] for AML and French-American-
British classiﬁcation of M0/M6/M7 or others for AML, clinical subtypes
according to criteria of the Japanese Lymphoma Study Group for ATL [5], the
incidence of CMV infection, disease and antigenemia, bacterial infection,
fungal infection, viral infection other than CMV, aGVHD, the conditioning
regimen, and institution where patients received allo-SCT. The most
appropriate models were selected based on Akaike’s information criteria. All
analyses were performed using SAS version 9.2 software (SAS Institute, Cary,
NC). Values of P < .05 were considered signiﬁcant in all analyses.
RESULTS
Patient Characteristics and Transplantation Conditions
In 228 patients who received allo-SCT in our study, 7 AML,
2 ALL/LBL, and 9 ATL patients experienced graft failure and/
or rejection. The rate of graft failure and/or rejection was not
statically difference among the 3 groups.
The characteristics of remaining 210 patients are shown in
Table 1. All ATL and ALL/LBL patients received standard-dose
chemotherapy before the procedure of transplantation, but
10 AML patients did not receive any chemotherapy before
allo-SCT. Sixteen related donors for ATL patients showed
a positive result for the anti-HTLV-1 antibody. Peripheral
blood mononuclear cells of these donors were subjected to
Southern blot analysis to examine the monoclonal integra-
tion of the HTLV-1 provirus into the genome, and all 16
donors were conﬁrmed as carriers of HTLV-1.
Table 1
Patient Characteristics
AML ALL/LBL ATL
No. of patients 91 51 68
Median age at allo-SCT (range) 42
(17-70)
32
(16-60)
51
(30-67)
Male sex 41 21 42
Disease classiﬁcation
AML (French-America-British)
M0 6
M1 9
M2 36
M3 5
M4 19
M5 6
M6 7
M7 1
Others 2
AML cytogenetic risk group*
Favorable 18
Intermediate 46
Adverse 21
Unknown 6
ALL cytogenetic
t(9;22) 17
Normal 13
Others 17
Unknown 4
ATL subtype
Acute 50
Lymphoma 17
Chronic 1
Disease status at allo-SCT
CR 39 38 15
PR - - 21
Relapse/Induction failure 42 13 32
Untreated 10 0 0
Donor
HLA-matched related donor 46 21 37
Alternative donor 45 30 31
HLA matching
0 mismatched loci 73 35 47
1 mismatched locus 5 7 6
2 mismatched locus 13 9 15
Source of stem cells
Bone marrow 56 31 30
Peripheral blood stem cell 23 14 20
Cord blood 12 6 18
Conditioning regimen
Myeloabrative 74 45 32
Reduced-intensity Myeloabrative 17 6 36
GVHD prophylaxis
Cyclosporine A þ sMTX 45 22 33
Cyclosporine A  others 3 1 10
Tacrolimus þ sMTX 31 25 15
Tacrolimus  others 12 3 10
Prophylaxis for fungal infection
Itraconazole 51 29 40
Fluconazole 22 12 20
Micafungin 13 7 5
Voriconazole 3 1 3
Amphotericin 2 2 0
Acute GVHD
Grade 0 47 18 40
Grade I 17 9 5
Grade II-IV 27 24 23
Chronic GVHD
Absent 40 19 34
Limited type 15 10 5
Extensive type 29 18 16
Anti-HTLV-1 antibody of donor
Positive 0 0 16
Negative 91 51 52
CMV serostatus of recipient
Positive 52 30 37
Negative 7 5 0
Unknown 32 16 31
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reduced intensity conditioning regimens than patients with
AML or ALL/LBL. Reduced-intensity conditioning using anti-
thymocyte globulin was administered to 2 ATL patients. In
general, HLA matched unrelated bone marrow recipients
were more likely to receive tacrolimus-based GVHD
prophylaxis than those who received allo-SCT using other
stem cell sources. No patients received in vitro T cell-
depleted transplantation. The procedure of prophylaxis for
fungal infection was similar among 3 groups.
The median time to engraftment was 16 days (range, 7 to
29 days), 16 days (range, 10 to 45 days), and 16 days (range, 9
to 32 days) in AML, ALL/LBL, ATL groups, respectively. Acute
GVHD developed in 44 AML (48.4%), 33 ALL/LBL (64.7%), and
28 ATL patients (41.2%). Severe acute GVHD (grade II-IV) was
observed in 27 AML (29.7%), 24 ALL/LBL (47.1%), 23 ATL
patients (33.8%). In 84 AML, 47 ALL/LBL, and 55 ATL patients
who were alive for over 100 days after transplantation,
chronic GVHD developed in 44 AML (52.4%), 28 ALL/LBL
(59.6%), and 21 ATL patients (38.2%). Extensive chronic GVHD
was observed in 29 AML (34.5%), 18 ALL/LBL (38.3%), 16 ATL
patients (29.1%).
CMV Antigenemia, Disease, and Infection
The characteristics of CMV infection (CMV antigenemia
and CMV disease) are shown in Table 2. The incidence of CMV
antigenemia without CMV disease in the ATL group was
similar to that in AML and ALL/LBL groups. One AML patient
and 3 ALL/LBL patients with CMV antigenemia improved
spontaneously, but all ATL patients received GCV and/or
foscarvir with or without intravenous gamma globulin. CMV
disease was documented in 13 of 91 AML patients (14.3%), 9
of 51 ALL/LBL patients (17.6%), and 15 of 68 ATL patients
(22.1%). In patients who developed CMV disease, 2 AML and 4
ATL patients developed CMV diseases despite preemptive
therapy for prior CMV antigenemia. Cumulative incidence of
CMV infection at 100 days and 1 year were followed: 51.7%
(95% CI: 40.7% to 61.5%) and 54.4% (95% CI: 43.2% to 64.3%) in
AML groups, 63.9% (95% CI: 48.5% to 75.8%) and 63.9% (95%
CI: 48.5% to 75.8%) in ALL/LBL groups, and 67.5% (95% CI:
54.3% to 77.7%) and 69.2% (95% CI: 56.0% to 79.2%) in ATL
groups. There was a signiﬁcant difference in the cumulative
incidence of CMV infection between AML and ATL groups
(AML versus ATL, P ¼ .0255; ALL/LBL versus ATL, P ¼ .7011).
Among the patients with episodes of CMV infection,
although all 32 ALL/LBL patient experienced the ﬁrst CMV
infection from engraftment to 100 days after allo-SCT (post-
engraftment phase), 2 of 48 AML (4.2%) and 1 of 45 ATL
patients (2.2%) experienced CMV antigenemia as ﬁrst CMV
infection after 100 days (late phase). In patients who expe-
rienced the improvement of CMV infection once, 12 of 46
AML (26.1%), 11 of 32 ALL/LBL (34.4%), and 15 of 43 ATL
patients (34.9%) developed recurrent CMV infection.
All 12 CMV-seronegative patients received trans-
plantation form CMV-seropositive donors. In these CMV-
seronegative patients, 3 of 7 AML and 2 of 5 ALL/LBLAML indicates acute myeloid leukemia; ALL, acute lymphoblastic leukemia;
LBL, lymphoblastic lymphoma; ATL, adult T cell leukemia/lymphoma; allo-
SCT, allogeneic hematopoietic stem cell transplantation; CR, complete
remission; PR, partial remission; sMTX, short-term methotrexate; GVHD,
graft versus host disease; CMV, cytomegalovirus.
* Based on the karyotype of leukemia cells, patients were classiﬁed into
either the favorable, intermediate, or adverse risk group, deﬁned by the
Medical Research Council group.
Table 2
CMV Infection
AML
(n ¼ 91)
ALL/LBL
(n ¼ 51)
ATL
(n ¼ 68)
CMV infection
Antigenemia without CMV
disease
36 (39.6%) 23 (45.1%) 30 (44.1%)
Pneumonia 5 (5.5%) 3 (5.9%) 8 (11.8%)
Gastroenteritis 7 (7.7%) 3 (5.9%) 4 (5.9%)
Hepatitis 0 3 (5.9%) 0
Pneumonia and Gastritis 1 (1.1%) 0 2 (2.9%)
Gastroenteritis and Hepatitis 0 0 1 (1.5%)
AML indicates acute myeloid leukemia; ALL, acute lymphoblastic leukemia;
LBL, lymphoblastic lymphoma; ATL, adult T cell leukemia/lymphoma.
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disease.
Pathogens Other Than CMV That Caused Clinical
Infection after Transplantation
Table 3 shows infectious agents other than CMV. Cumu-
lative incidence of bacterial infection at 100 days and 1 year
were followed: 13.4% (95% CI: 7.3% to 21.3%) and 16.0% (95%
CI: 9.2% to 24.5%) in AML groups, 11.8% (95% CI: 4.7% to 22.3%)
and 11.8% (95% CI: 4.7% to 22.3%) in ALL/LBL groups, and
20.9% (95% CI: 12.1% to 31.4%) and 23.0% (95% CI: 13.5% to
34.0%) in ATL groups. The ATL group showed the highest
cumulative incidence of bacterial infection, but there was no
signiﬁcant difference among the 3 groups (data not shown).
Serious bacterial infections were documented among
37 patients (sepsis, n ¼ 27; pneumonia, n ¼ 9; meningitis,
n ¼ 1). Three ATL patients exhibited Pseudomonas aeruginosa
infection (pneumonia, n ¼ 2; sepsis, n ¼ 1), but none in AML
and ALL/LBL groups did.
Cumulative incidence of fungal infection at 100 days and
1 year were followed: 2.2% (95% CI: 0.4% to 7.0%) and 5.8%
(95% CI: 2.1% to 12.2%) in AML groups, 2.0% (95% CI: 0.2% toTable 3
Infectious Agents Other than CMV
Pathogen Pre-engraftment (Days 0 to
Engraftment)
P
D
AML group
(n ¼ 91)
Bacteria Gram-positive organism (n ¼ 4)
Gram-negative organism (n ¼ 2)
G
Fungus Aspergillus spp (n ¼ 1) A
Virus* None H
A
H
V
B
E
ALL/LBL group
(n ¼ 51)
Bacteria Gram-positive organism (n ¼ 3) G
Fungus None C
Virus* BK virus (n ¼ 1) H
A
H
I
ATL group
(n ¼ 68)
Bacteria Gram-positive organism (n ¼ 6)
Gram-negative organism (n ¼ 5)
G
G
Fungus Aspergillus spp (n ¼ 1) C
A
Virus* Human herpes virus 6 (n ¼ 2)
Adenovirus (n ¼ 1)
BK virus (n ¼ 2)
H
A
V
B
AML indicates acute myeloid leukemia; ALL, acute lymphoblastic leukemia; LBL, ly
* Virus did not include CMV infection.9.3%) and 6.4% (95% CI: 1.6% to 16.1%) in ALL/LBL groups, and
7.5% (95% CI: 2.7% to 15.5%) and 9.4% (95% CI: 3.8% to 18.2%) in
ATL groups. The ATL group showed the highest cumulative
incidence of invasive fungal infection, without a signiﬁcant
difference among the three groups (data not shown). In total,
3 patients (2 with ATL and 1 with ALL/LBL) developed PJP
without prophylactic oral trimethoprim-sulfamethoxazole,
but none did in the AML group, even without the prophy-
laxis. Two ATL patients developed PJP with CR, at day 18 and
137 after allo-SCT, respectively. One ALL patient also devel-
oped PJP coincident with the relapse of ALL at day 392 after
allo-SCT.
Cumulative incidence of viral infection other than CMV at
100 days and 1 year were followed: 15.9% (95% CI: 9.3% to
24.1%) and 29.1% (95% CI: 19.6% to 39.3%) in AML groups,
15.9% (95% CI: 7.4% to 27.3%) and 22.3% (95% CI: 11.8% to
34.9%) in ALL/LBL groups, and 24.5% (95% CI: 14.8% to 35.5%)
and 33.1% (95% CI: 21.2% to 45.5%) in ATL groups. There was
no signiﬁcant difference among the 3 groups in the cumu-
lative incidence of viral infections other than CMV (AML
versus ALL/LBL versus ATL ¼ 31.2% versus 25.0% versus 33.1%
at 3 years) (data not shown).Death Caused by Infections
Cumulative infection-related mortalities at 100 days and
1 year were followed: 2.3% (95% CI: 0.4% to 7.2%) and 6.1%
(95% CI: 2.2% to 12.7%) in AML groups, 0.0% (95% CI: 0.2% to
9.5%) and 2.0% (95% CI: 0.2% to 9.5%) in ALL/LBL groups, and
9.4% (95% CI: 3.8% to 18.2%) and 14.7% (95% CI: 7.1% to 24.8%)
in ATL groups. The ATL group showed the highest mortality,
which was signiﬁcantly greater than that of the other 2
groups (AML versus ATL, P ¼ .0496; ALL/LBL versus ATL,
P ¼ .0075) (Figure 1A). However, in all 210 patients, ATL was
not a signiﬁcant factor despite the high hazard rate for
infection-related mortality on multivariate analysis (Hazard
rate (HR) 2.283; 95% conﬁdence interval (CI): 0.834 to 6.251,ost-engraftment (Engraftment to
ays þ100)
Late Phase (Days 100 to >365)
ram-positive organism (n ¼ 6) Gram-positive organism (n ¼ 3)
Gram-negative organism (n ¼ 1)
spergillus spp (n ¼ 1) Candida spp (n ¼ 2)
Aspergillus spp (n ¼ 2)
uman herpes virus 6 (n ¼ 5)
denovirus (n ¼ 1)
erpes simplex virus (n ¼ 3)
aricella-zoster virus (n ¼ 2)
K virus (n ¼ 2)
pstein-Barr virus (n ¼ 1)
Human herpes virus 6 (n ¼ 1)
Adenovirus (n ¼ 1)
Herpes simplex virus (n ¼ 1)
Varicella-zoster virus (n ¼ 7)
Epstein-Barr virus (n ¼ 1)
ram-positive organism (n ¼ 1) None
andida spp (n ¼ 1) Mucor spp (n ¼ 1)
Aspergillus spp (n ¼ 2)
Pneumocystic jirovecii (n ¼ 1)
uman herpes virus 6 (n ¼ 3)
denovirus (n ¼ 3)
erpes simplex virus (n ¼ 1)
nﬂuenza virus (n ¼ 1)
Varicella-zoster virus (n ¼ 4)
ram-positive organism (n ¼ 1)
ram-negative organism (n ¼ 3)
Gram-positive organism (n ¼ 3)
Gram-negative organism (n ¼ 2)
andida spp (n ¼ 2)
spergillus spp (n ¼ 3)
Aspergillus spp (n ¼ 2)
Pneumocystic jirovecii (n ¼ 1)
uman herpes virus 6 (n ¼ 2)
denovirus (n ¼ 5)
aricella-zoster virus (n ¼ 3)
K virus (n ¼ 1)
Herpes simplex virus (n ¼ 1)
Varicella-zoster virus (n ¼ 3)
mphoblastic lymphoma; ATL, adult T cell leukemia/lymphoma.
Figure 1. Cumulative incidence of infection-related death after transplantation. The 95% conﬁdence intervals at 1, 3, 5, and 10 years are shown in each infection-
related mortality. (A) Infectious mortality was higher in the adult T cell leukemia/lymphoma (ATL) group than that in the 2 other groups. (B) In the ATL group,
infectious mortalities were higher in patients with episodes of cytomegalovirus (CMV) infection than in those without, but the P value for this association was near
the borderline of signiﬁcance.
Table 4
Agents of Infection-Related Death
Post-engraftment Phase
to Days þ100)
Late Phase (Days 100
to >365)
AML group
(n ¼ 91)
MRSA (n ¼ 1)
Enterococcus spp (n ¼ 1)
Aspergillus spp (n ¼ 1)
Cytomegarovirus (n ¼ 1)
Escherichia coli (n ¼ 1)
Candida spp (n ¼ 2)
Cytomegarovirus (n ¼ 1)
ALL/LBL group
(n ¼ 51)
none Adenovirus (n ¼ 1)
ATL group
(n ¼ 68)
Enterococcus spp (n ¼ 1)
Stenotrophomonas maltophilia
(n ¼ 1)
Pneumocystis jirovecii (n ¼ 1)
Human herpes virus-6 (n ¼ 1)
Adenovirus (n ¼ 1)
Cytomegarovirus (n ¼ 1)
MRSA (n ¼ 1)
Pseudomonas aeruginosa
(n ¼ 3)
Pneumocystis jirovecii
(n ¼ 1)
Cytomegarovirus (n ¼ 1)
MRSA indicates methicillin-resistant Staphylococcus aureus; AML, acute
myeloid leukemia; ALL, acute lymphoblastic leukemia; LBL, lymphoblastic
lymphoma; ATL, adult T cell leukemia/lymphoma.
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at allo-SCT was a signiﬁcant unfavorable factor for infection-
related mortality (HR 2.528; 95% CI: 1.007 to 6.345,
P ¼ .0482).
Although nonremission at allo-SCT remained a signiﬁcant
risk factor for infection-relatedmortality in AML group, it did
not in ALL/LBL and ATL groups. Rather, in the ATL group,
infection-related mortality was higher among patients who
experienced a CMV infection after allo-SCT than those who
did not, but the P value was at the borderline of signiﬁcance
(P ¼ .0569) (Figure 1B). There was no signiﬁcant relationship
between episodes of CMV infection and mortality caused by
infection in either the AML or ALL/LBL group (AML group,
P ¼ .3160; ALL/LBL group, P ¼ .4461). Additionally, to exclude
the bias due to the CMV-serostatus of patients, infection-
related mortalities were analyzed in patients who were
CMV-seropositive in each of the 3 groups. For CMV-
seropositive patients, the comparison of cumulative
infection-related mortalities between those with episodes of
CMV infection andwithout showed a signiﬁcant difference in
the ATL group; the episodes of CMV infection have a signiﬁ-
cant negative impact on infection-related mortalities in the
ATL group (P¼ .0492), but not in the AML and ALL/LBL groups
(P ¼ .0840 and P ¼ .4276, respectively).
The difference of institution did not have any impact on
the cumulative infection-related mortalities in each of the 3
groups. In the ATL group, the HTLV-1 serostatus of donor was
not associated with cumulative infection-related mortalities.
The pathogens resulting in fatal infectious complications
are shown in Table 4. Interestingly, despite the high inci-
dence of CMV infection after allo-SCT, 4 patients died of CMV
diseases (CMV pneumonia in 2 ATL and 2 AML patients), and
no ALL/LBL patient died of any CMV disease. Of these
4 patients, one with AML and one with ATL died of recurrent
CMV infection on late phase. In the patients who died of
infection on late phase, 4 of 6 with ATL, 1 of 4 with AML and
none with ALL/LBL died of bacterial infection. The proportion
of bacteria in the pathogens resulting in fatal infectious
complications on late phase after allo-SCT was likely to be
higher in the ATL group than in the AML and ALL/LBL groups,
but this difference was not signiﬁcant. The pathogens
inducing fatal complications in the 4 ATL patients on late
phase were either methicillin-resistant Staphylococcus
aureus or Pseudomonas aeruginosa, which were resistant to
many antibiotic agents. Also, these 4 patients with ATLexperienced the improvement of CMV antigenemia by GCV
on post-engraftment phase (ie, before the development of
fatal bacterial infections).
Survival
The outcomes of allo-SCT in each of the 3 groups are
shown in Table 5. Median survival times after allo-SCT were
4.0 years and 1.0 year in the AML group and ATL group,
respectively. Median survival was not reached in the ALL/LBL
group (Figure 2A). Estimated OS after transplantation were
49.9% (95% CI: 38.2% to 60.5%), 58.3% (95% CI: 41.2% to 71.9%),
and 34.9% (95% CI: 23.2% to 46.8%) at 5 years in the AML,
ALL/LBL, and ATL groups, respectively. OS for ATL patients
was signiﬁcantly worse than that for AML (P ¼ .0089) and
ALL/LBL groups (P ¼ .0023), while OS rates for AML and
ALL/LBL patients were similar (P ¼ 0.2982).
Univariate Analysis for Survival
Univariate analysis for survival identiﬁed several pre-
transplantation and post-transplantation factors. The disease
status (CR or PR) at transplantation had a signiﬁcant positive
impact in both the AML (P < .0001) and ALL/LBL groups
(P¼ .0050), but not in the ATL group. The existence of aGVHD
(grade II-IV) was associated with worse survival in the AML
group (P¼ .0007). AML patients with cGVHD (extensive type)
(P ¼ .0302) and ATL with cGVHD (limited type) (P ¼ .0140)
Table 5
Transplantation Outcome
AML
(n ¼ 91)
ALL/LBL
(n ¼ 51)
ATL
(n ¼ 68)
Alive (dead) 48 (43) 33 (18) 25 (43)
Cause of death
Bacterial infection 3 - 6
Fungal infection 3 - 2
CMV disease 2 - 2
Viral infection other than CMV - 1 2
Disease progression 24 12 21
GVHD with or without any
infection
5 2 4
Bleeding 1 - 2
Organ failure without any
infection
5 3 3
Secondary malignancy - - 1
AML indicates acute myeloid leukemia; ALL, acute lymphoblastic leukemia;
LBL, lymphoblastic lymphoma; ATL, adult T cell leukemia/lymphoma; CMV,
cytomegalovirus; GVHD, grant-versus-host disease.
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infection provided a negative impact on OS for the AML (P ¼
.0015) and ALL/LBL groups (P ¼ .0459). Episodes of bacterial
infection (P ¼ .0102) and CMV infection (P ¼ .0184) had
a signiﬁcant negative impact in the ATL group (Figure 2B, C).
In CMV-seropositive patients of each of the 3 groups, episode
of CMV infection negatively affected survival with a border-
line difference in the ATL groups (P¼ .0615), but therewas noFigure 2. Kaplan-Meier estimate of overall survival after transplantation. The 95% con
(A) OS of the adult T cell leukemia/lymphoma (ATL) group was signiﬁcantly worse
leukemia/lymphoblastic lymphoma (ALL/LBL) group. (B) In ATL group, the OS of patie
than those without. (C) In the ATL group, the OS of patients with episodes of bacterirelationship in the AML and ALL/LBL groups (P ¼ .4680 and
P ¼ .4620, respectively).
There was no signiﬁcant relationship between the
difference of institution and OS in each of the 3 groups. For
the ATL group, neither the use of anti-thymocyte globulin in
the conditioning regimen nor the HTLV-1 serostatus of donor
was associated with survival.Multivariate Analysis for Survival
Multivariate analysis in all 210 patients revealed 6 factors
that adversely affected OS: ATL (HR 1.944; 95% CI: 1.204 to
3.141, P ¼ .0066), older age (HR 2.204; 95% CI 1.364 to 3.562,
P ¼ .0012), nonremission (HR 3.153; 95% CI 2.041 to 4.868,
P < .0001), bacterial infection (HR 2.121; 95% CI 1.267 to
3.550, P ¼ .0042), fungal infection (HR 2.718; 95% CI 1.507 to
4.901, P¼ .0009), and myeloabrative conditioning (HR 2.064;
95% CI 1.149 to 3.707, P ¼ .0154).
To clarify the distinct unfavorable features in ATL groups,
we also performed multivariate analysis for survival
respectively in each of the 3 groups (Table 6). There were 4
factors that adversely affected OS in the AML group: patient
age ( 42 years; HR 2.283; 95% CI: 1.164 to 4.476, P ¼ .0163),
lack of CR at transplantation (HR 2.975; 95% CI: 1.285 to
6.888, P ¼ .0109), the existence of aGVHD (grade II-IV) (HR
1.731; 95% CI: 1.327 to 2.258, P < .0001), and episodes of
fungal infection (HR 3.934; 95% CI: 1.357 to 11.406, P¼ .0117).
In the ALL/LBL group, 2 factors were associated with worseﬁdence intervals at 1, 3, 5, and 10 years are shown in each overall survival (OS).
than that of either the acute myeloid leukemia (AML) or acute lymphoblastic
nts with episodes of cytomegalovirus (CMV) infection was signiﬁcantly worse
al infection was signiﬁcantly worse than those without.
Table 6
Multivariate Analysis of Risk Factors for Overall Survival
AML ALL/LBL ATL
P Value Hazard Ratio P Value Hazard Ratio P Value Hazard Ratio
Age  median age P ¼ .0163 2.283 Not selected P ¼ .3487 1.363
Without CR or PR at allo-SCT P ¼ .0109 2.975 P ¼ .0058 3.874 Not selected
aGVHD (grade II -IV) P < .0001 1.731 Not selected Not selected
Unrelated BM Not selected Not selected P ¼.0248 2.568
Cord blood Not selected Not selected P ¼ .8645 0.936
CMV infection Not selected Not selected P ¼ .0171 2.514
Invasive fungal infection P ¼ .0117 3.934 P ¼ .0448 3.430 Not selected
AML indicates acute myeloid leukemia; ALL, acute lymphoblastic leukemia; LBL, lymphoblastic lymphoma; ATL, adult T cell leukemia/lymphoma; CR, complete
remission; PR, partial remission; GVHD, grant-versus-host disease; BM, bone marrow; CMV, cytomegalovirus.
In the ATL group, episodes of CMV infection signiﬁcantly correlated with worse overall survival. However, there was no such association in either the AML or
ALL/LBL group.
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1.481 to 10.134, P ¼ .0058) and episodes of fungal infection
(HR 3.430; 95% CI: 1.029 to 11.435, P ¼ .0448). In the ATL
group, 2 factors that differed from those in the AML or ALL/
LBL group had a negative impact on OS with signiﬁcance: the
use of unrelated bone marrow (HR 2.568; 95% CI: 1.127 to
5.854, P ¼ .0248) and episodes of CMV infection (HR 2.514;
95% CI: 1.178 to 5.366, P ¼ .0171). Although the difference of
institution was analyzed in multivariate analysis as a factor,
this difference was not selected as a factor in each of 3
groups.
DISCUSSION
The success or failure of allo-SCT is mostly determined in
the ﬁrst 6 months after allo-SCT. Outcome closely correlates
with the reconstitution of donor cell derived immunity,
which affects the survival of recipients through GVHD and
the graft-versus-leukemia effect, and the degree of immune
competence achieved against infectious agents. Recently,
some reports have indicated that the incidence of fungal
infection and CMV infection has increased after engraftment,
particularly among patients with severe immunodeﬁciency.
For example, after allo-SCT using in vitro or in vivo T cell
depletion, fungal infection, and reactivation of the Epstein-
Barr virus and CMV are closely related to serious complica-
tions [42-49]. Also, the risk of infectious complications,
including HHV-6 encephalitis and CMV diseases, is higher in
patients who received cord blood transplantation [42,50-54].
These results suggest that the incidence of infectious
complications depends not only on infectious disease-
causing pathogens but also on the background of the
patient or the cause of immunosuppression.
In our study, although the cumulative incidence of either
bacterial or fungal infection was similar among the 3 groups,
the ATL group showed the highest cumulative incidence of
infection-related death, mainly caused by these infections.
Importantly, bacteria resistant to many antibiotic agents
emerged as a cause of death after 100 days in patients with
ATL. It is suggested that after allo-SCT, these patients would
be more susceptible to life-threatening bacterial infections
even on late phase, compared to those with acute leukemia,
and that the current strategy for infection would not be
sufﬁcient for allo-SCT to ATL. Hence, it seems that the
development of an adoptive strategy in post-transplant
patients with ATL is required.
The appearance of a CMV infection showed a negative
impact for OS as an independent variable in the ATL group.
Interestingly, while there were only 2 patients with ATL
having CMV disease at the time of death, the risk ofinfectious death in patients with ATL who experienced CMV
infection (including CMV antigenemia) was likely to be
higher. Namely, episodes of CMV infection could predict
a higher risk of death caused by not only CMV disease, but
also other infections, which may help to identify the ATL
patients who should receive more intensive management for
infection.
It is not clear why episodes of CMV infection correlated
with the outcome of patients with ATL, althoughmultivariate
analysis identiﬁed episodes of CMV infection as an inde-
pendent variable only in the ATL group. It has been shown
that episodes of CMV infection were associated with a worse
outcome in post-transplant patients with defective cellular
immunity [43,44,55]. Therefore, it is speculated that persis-
tent compromised cellular immunity after transplantation
led to the higher susceptibility of CMV and other infections
among ATL patients, resulting in worse outcomes than
leukemia patients. Considering that the reactivation of CMV
itself and the prolonged administration of GCV could induce
greater immune suppression [56,57], we hypothesize that
the direct and indirect inﬂuence of CMV infection adversely
promoted immunosuppression attendant on ATL patients. It
remains to be elucidated how immunologic recovery was
delayed after transplantation in ATL patients. Since the
immune system recovery following allo-SCT was not sufﬁ-
ciently evaluated in our study, the monitoring of immune
function after transplant, such as analysis of lymphocyte
subset and quantitative estimation of immunoglobulin,
should be considered in a future study.
It is possible that CMV-serostatus affected the result of
statistical analysis in our study, because CMV-serostatus,
which was unexamined in 37.6% patients, was not included
in the statistical analysis. Therefore, to remove the bias of this
point, the analysis for ATL patients with CMV-seropositive
revealed that CMV infection was also identiﬁed as a risk
factor in infection-related mortality and OS. Considering that
it has been reported that about 90% of the Japanese pop-
ulation tests CMV-seropositive, the difference of CMV-
serostatus would not have a big impact in our study.
However, a larger analysis for matched patients’ background
regarding with CMV-serostatus would help to conﬁrm our
ﬁndings.
The ATL group showed that the highest cumulative inci-
dence of infection-related mortality and the various patho-
gens causing death, indicating that it was difﬁcult to
establish the uniform management to reduce the fetal
infectious complications for post-transplant patients with
ATL. However, it is speculated that more intensive manage-
ment for bacterial infection might provide the reduction of
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with ATL, since ATL group would be more likely to show the
higher risk of fatal antibiotic-resistant bacterial infection,
even on late phase in our study. Therefore, appropriate
antibiotic treatment using prolonged bacterial surveillance
culture should be considered, particularly in ATL patients
with persistent compromised cellular immunity. Moreover,
because of a limitation of treatment active on multi-drug
resistant gram negative rods, particularly Pseudomonas aer-
uginosa, at the present situation, the introduction of new
treatment options, including antibiotic combination therapy
using a “break-point checker board plate” and developing
antibiotic agents such as colistin [58-62], are expected in
patients who developed such infection after allo-SCT.
Our results showed the higher risk of fatal infectious
complications in post-transplant patients with ATL.
However, the number of patients is limited and the detailed
treatment protocols were not completely uniform. Thus, it is
possible that these factors exerted a bias and affected results.
For instance, the small number of patients in our study
resulted in wide and overlapping conﬁdence intervals
despite P values <.05. Our ﬁnding should be interpreted
carefully, and they should be conﬁrmed in larger prospective
studies.
In conclusion, we found that the clinical features of
infectious complications after allo-SCT in ATL patients are
different from those in AML and ALL/LBL patients. Because
allo-SCT offers the best chance of prolonged survival by
inducing graft-versus-ATL effect, developing supportive care
to minimize fatal infectious complications would be impor-
tant, in particular, for post-transplant patients with ATL. Our
data suggested that ATL patients require more intensive
management for infections according to individualized risk
such as the appearance of CMV infection. Such a strategymay
be beneﬁcial in reducing transplantation-relatedmortality in
post-transplant patients with ATL.ACKNOWLEDGMENTS
We thank the patients who willingly entered this study;
the physicians, nurses, and other support staff who cared for
the patients during the transplantation procedures; and the
clinical investigation team at each participating institution
who provided data collection and follow-up.
Financial disclosure: This study was supported in part by
a Grant-in-Aid from the Ministry of Health, Labour, and
Welfare of Japan.
Conﬂict of Interest Statement: There are no conﬂicts of
interest to report.
Authorship Statement: H.I., J.T., T.F., and Y. M-i contributed
to the study concept/design. H.I., J.T., T.F., H.T., S.S., K.A., Y.S.,
E.M., R.Y., Y.O., D.I., Y.I., S.Y., T.H., Y. Mo., and Y.Mi. performed
data collection/analysis. H.I., S.H., and Y. Mi. performed
statistical analysis. H.I., J.T., T.F., H.T., and Y. Mi. drafted the
manuscript and created ﬁgures/tables. H.I., J.T., T.F., H.T., S.S.,
K.A., Y.S., E.M., R.Y., Y.O., D.I., Y.I., S.Y., T.H., Y. Mo., S.H., and
Y.Mi. reviewed the manuscript and read and approved the
ﬁnal version of the manuscript.REFERENCES
1. Uchiyama T, Yodoi J, Sagawa K, et al. Adult T-cell leukemia: clinical and
hematologic features of 16 cases. Blood. 1977;50:481-492.
2. Poiesz BJ, Ruscetti FW, Gazdar AF, et al. Detection and isolation of type
C retrovirus particles from fresh and cultured lymphocytes of a patient
with cutaneous T-cell lymphoma. Proc Natl Sci USA. 1980;77:
7415-7419.3. Hinuma Y, Nagata K, Hanaoka M, et al. Adult T-cell leukemia: antigen in
an ATL cell line and detection of antibodies to the antigen in human
sera. Proc Natl Acad Sci USA. 1981;78:6476-6480.
4. Yoshida M, Seiki M, Yamaguchi K, et al. Monoclonal integration of
human T-cell leukemia provirus in all primary tumors of adult T-cell
leukemia suggests causative role of human T-cell leukemia virus in the
disease. Proc Natl Acad Sci USA. 1984;81:2534-2537.
5. Shimoyama M. Diagnostic criteria and classiﬁcation of clinical subtypes
of adult T-cell leukemia-lymphoma: A report from the Lymphoma
Study Group (1984-87). Br J Haematol. 1991;79:428-437.
6. Yamada Y, Tomonaga M, Fukuda H, et al. A new G-CSF-supported
combination chemotherapy, LSG15, for adult T-cell leukemia-
lymphoma: Japan Clinical Oncology Group Study 9303. Br J Haematol.
2001;113:375-382.
7. Tsukasaki K, Utsunomiya A, Fukuda H, et al. VCAP-AMP-VECP
compared with biweekly CHOP for adult T-cell leukemia-lymphoma:
Japan Clinical Oncology Group Study JCOG9801. J Clin Oncol. 2007;25:
5458-5464.
8. Utsunomiya A, Miyazaki Y, Yakatsuka Y, et al. Improved outcome of
adult T cell leukemia/lymphoma with allogeneic hematopoietic stem
cell transplantation. Bone Marrow Transplant. 2001;27:15-20.
9. Kami M, Hamaki T, Miyakoshi S, et al. Allogeneic haematopoietic stem
cell transplantation for the treatment of adult T-cell leukemia/
lymphoma. Br J Haematol. 2003;120:304-309.
10. Fukushima T, Miyazaki Y, Honda S, et al. Allogeneic hematopoietic
stem cell transplantation provides sustained long-term survival for
patients with adult T-cell leukemia/lymphoma. Leukemia. 2005;19:
829-834.
11. Okamura J, Utsunomiya A, Tanosaki R, et al. Allogeneic stem-cell
transplantation with reduced intensity as novel immunotherapy and
antiviral therapy for adult T-cell leukemia/lymphoma. Blood. 2005;105:
4143-4145.
12. Kato K, Kanda Y, Eto T, et al. Allogeneic bone marrow transplantation
from unrelated human T-cell leukemia virus-1-negative donors for
adult T-cell leukemia/lymphoma: retrospective analysis of data from
the Japan Marrow Donor Program. Biol Blood Marrow Transplant. 2007;
13:90-99.
13. Tanosaki R, Uike N, Utsunomiya A, et al. Allogeneic hematopoietic stem
cell transplantation using reduced-intensity conditioning for adult
T-cell leukemia/lymphoma: impact of antithymocyte globulin on
clinical outcome. Biol Blood Marrow Transplant. 2008;14:702-708.
14. Hishizawa M, Kanda J, Utsunomiya A, et al. Transplantation of alloge-
neic hematopoietic stem cells for adult T-cell leukemia: a nationwide
retrospective study. Blood. 2010;116:1369-1376.
15. Kanda J, Hishizawa M, Utsunomiya A, et al. Impact of graft-versus-host
disease on outcomes after allogeneic hematopoietic cell trans-
plantation for adult T-cell leukemia: a retrospective cohort study.
Blood. 2012;119:2141-2148.
16. Ishida T, Hishizawa M, Kato K, et al. Allogeneic hematopoietic stem cell
transplantation for adult T-cell leukemia-lymphoma with special
emphasis on preconditioning regimen: a nationwide retrospective
study. Blood. 2012;120:1734-1741.
17. Itonaga H, Tsushima H, Taguchi J, et al. Treatment of relapsed adult
T-cell leukemia/lymphoma after allogeneic hematopoietic stem cell
transplantation: the Nagasaki Transplant Group experience. Blood
doi:10.1182/blood-2012-07-444372.
18. Suzumiya J, Marutsuka K, Nabeshima K, et al. Autopsy ﬁndings in 47
cases of adult T-cell leukemia/lymphoma in Miyazaki prefecture. Japan.
Leuk Lymphoma. 1993;11:281-286.
19. Uchiyama T. Human T cell leukemia virus type I (HTLV-I) and human
diseases. Annu Rev Immunol. 1997;15:15-37.
20. Yasunaga J, Sakai T, Nosaka K, et al. Impaired production of naïve
T lymphocytes in human T-cell leukemia virus type I-infected indi-
viduals: Its implications in the immunodeﬁcient state. Blood. 1993;97:
3177-3183.
21. Chen S, Ishii N, Ine S, et al. Regulatory T cell-like activity of Foxp3þ
adult T cell leukemia cells. Int Immunol. 2006;18:269-277.
22. Ogata M, Satou T, Kawano R, et al. High incidence of cytomegalovirus,
human herpesvirus-6, and Epstein-Barr virus reactivation in patients
receiving cytotoxic chemotherapy for adult T cell leukemia. J Med Virol.
2011;83:702-709.
23. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus conference
on acute GVHD grading. Bone Marrow Transplant. 1995;15:825-828.
24. Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health
consensus development project on criteria for clinical trials in chronic
graft-versus-host disease: I. Diagnosis and Staging Working Group
report. Biol Blood Marrow Transplant. 2005;11:945-956.
25. Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing
infectious complications among hematopoietic cell transplantation
recipients: a global perspective. Biol Blood Marrow Transplant. 2009;15:
1143-1238.
26. Maertens J, Marchetti O, Herbrecht R, et al. European guidelines for
antifungal management in leukemia and hematopoietic stem cell
transplant recipients: summary of the ECIL 3d2009 update. Bone
Marrow Transplant. 2011;46:709-718.
H. Itonaga et al. / Biol Blood Marrow Transplant 19 (2013) 607e615 61527. Engelhard D, Akova M, Boeckh MJ, et al. Bacterial prevention after
hematopoietic cell transplantation. Bone Marrow Transplant. 2009;44:
467-470.
28. Kanda Y, Mineishi S, Saito T, et al. Long-term low-dose acyclovir
against varicella-zoster virus reactivation after allogeneic hematopoi-
etic stem cell transplantation. Bone Marrow Transplant. 2001;28:
689-692.
29. Junghanss C, Boeckh M, Carter RA, et al. Incidence and outcome of
cytomegalovirus infections following nonmyeloablative compared
with Myeloabrative allogeneic stem cell transplantation, a matched
control study. Blood. 2002;99:1978-1985.
30. Boeckh M, Gooley TA, Myerson D, et al. Cytomegalovirus pp65
antigenemia-guided early treatment with ganciclovir versus ganciclo-
vir at engraftment after allogeneic marrow transplantation: a ran-
domized double-blind study. Blood. 1996;88:4063-4071.
31. Boekh M, Bowden RA, Gooley T, et al. Successful modiﬁcation of a pp65
antigenemia-based early treatment strategy for prevention of cyto-
megalovirus disease in allogeneic marrow transplant recipients. Blood.
1999;93:1781-1782.
32. Tagawa M, Minematsu T, Masuzaki H, et al. Seroepidemilogical survey
of cmytpmegalovirus infection among pregnant women in Nagasaki,
Japan. Pediatr Int. 2010;52:459-462.
33. Hirota K, Muraguchi K, Watabe N, et al. Prospective study on maternal,
intrauterine, and perinatal infections with cytomegalovirus in Japan
during 1976-1990. J Med Virol. 1992;37:303-306.
34. Bowden RA, Slichter SJ, Sayers M, et al. A comparison of ﬁltered
leukocyte-reduced and cytomegalovirus seronegative blood products
for the prevention of transfusion-associated CMV infection after
marrow transplant. Blood. 1995;86:3598-3603.
35. Ascioglu S, Rex JH, de Pauw B, et al. Deﬁning opportunistic invasive
fungal infections in immunocompromised patients with cancer and
hematopoietic stem cell transplants: an international consensus. Clin
Infect Dis. 2002;34:7-14.
36. Ljungman P, Grifﬁths P, Paya C. Deﬁnitions of cytomegalovirus infec-
tion and disease in transplant recipients. Clin Infect Dis. 2002;34:
1094-1097.
37. La Rosa AM, Champlin RE, Mirza N, et al. Adenovirus infections in adult
recipients of blood and marrow transplants. Clin Infect Dis. 2001;32:
871-876.
38. Leung AY, Suen CK, Lie AK, Liang RH, Yuen KY, Kwong YL. Quantiﬁca-
tion of polyoma BK viruria in hemorrhagic cystis complicating bone
marrow transplantation. Blood. 2001;8:1971-1978.
39. Yoshikawa T, Suga S, Asano Y, et al. Human herpesvirus-6 infection in
bone marrow transplantation. Blood. 1991;78:1381-1384.
40. Grimwade D, Walker H, Oliver F, et al. The importance of diag-
nostic cytogenetic on outcome in AML: analysis of 1612 patients
entered into the MRC AML 10 trial. The Medical Research Council
Adult and Children’s Leukaemia Working Parties. Blood. 1998;92:
2322-2333.
41. Miyazaki Y, Kuriyama K, Miyawaki S, et al. Cytogenetic heterogenecity
of acute myeloid leukaemia (AML) with trilineage dysplasia: Japan
Adult Leukaemia Study Group-AML 92 study. Br J Haematol. 2003;120:
56-62.
42. Walker CM, van Burik JA, De For TE, Weisdorf DJ. Cytomegalovirus
infection after allogeneic transplantation: comparison of cord blood
with peripheral blood and marrow graft sources. Biol Blood Marrow
Transplant. 2007;13:1106-1115.
43. Broers AE, van Der Holt R, van Esser JW, et al. Increased transplant-
related morbidity and mortality in CMV-seropositive patients
despite highly effective prevention of CMV disease after allogeneic
T-cell-depleted stem cell transplantation. Blood. 2000;95:2240-
2245.
44. van Burik JA, Carter SL, Freifeld AG, et al. Higher risk of cytomegalo-
virus and aspergillus infections in recipients of T cell-depleted unre-
lated bone marrow: analysis of infectious complications in patients
treated with T cell depletion versus immunosuppressive therapy to
prevent graft-versus-host disease. Biol Blood Marrow Transplant. 2007;
13:1487-1498.45. Marr KA, Carter RA, Boeckh M, et al. Invasive aspergillosis in allogeneic
stem cell transplant recipients: change in epidemiology and risk
factors. Blood. 2002;100:4358-4366.
46. Schmidt-Hieber M, Schwarck S, Stroux A, et al. Immune reconstitution
and cytomegalovirus infection after allogeneic stem cell trans-
plantation: the important impact of in vivo T cell depletion. Int J
Hematol. 2010;9:877-885.
47. Park SH, Choi SM, Lee DG, et al. Infectious complications associated
with alemtuzumab use for allogeneic hematopoietic stem cell trans-
plantation: comparison with anti-thymocyte globulin. Transpl Infect
Dis. 2009;11:413-423.
48. Mohty M, Jacot W, Faucher C, et al. Infectious complications following
allogeneic HLA-identical sibling transplantation with antithymocyte
globulin-based reduced intensity preparative regimen. Leukemia. 2003;
17:2168-2177.
49. Hoegh-Petersen M, Goodyear D, Geddes MN, et al. High incidence of
post transplant lymphoproliferative disorder after antithymocyte
globulin-based conditioning and ineffective prediction by day 28 EBV-
speciﬁc T lymphocyte counts. Bone Marrow Transplant. 2011;46:
1104-1112.
50. Laughlin MJ, Eapen M, Rubinstein P, et al. Outcomes after trans-
plantation of cord blood or bone marrow from unrelated donors in
adults with leukemia. N Engl J Med. 2004;351:2265-2275.
51. Miyakoshi S, Kusumi E, Matsumura T, et al. invasive fungal infection
following reduced-intensity cord blood transplantation for adult
patients with hematologic diseases. Biol Blood Marrow Transplant.
2007;13:771-777.
52. Sashihara J, Tanaka-Taya K, Tanaka S, et al. High incidence of human
herpesvirus 6 infection with a high viral load in cord blood stem cell
transplants. Blood. 2002;100:2005-2011.
53. Matsumura T, Narimatsu H, Kami M, et al. Cytomegalovirus infections
following umbilical cord blood transplantation using reduced intensity
conditioning regimens for adult patients. Biol Blood Marrow Transplant.
2007;13:577-583.
54. Montesinos P, Sanz J, Cantero S, et al. Incidence, risk factors, and
outcome of cytomegalovirus infection and disease in patients receiving
prophylaxis with oral valganciclovir or intravenous ganciclovir after
umbilical cord blood transplantation. Biol Blood Marrow Transplant.
2009;15:730-740.
55. Nakamura R, Battiwalla M, Solomon S, et al. Persisting post-
transplantation cytomegalovirus antigenemia correlates with poor
lymphocyte proliferation to cytomegalovirus antigen and predicts for
increased late relapse and treatment. Biol Blood Marrow Transplant.
2004;10:49-57.
56. Bowden RA, Digel J, Reed EC, et al. Immunosuppressive effects of
ganciclovir on in vitro lymphocyte responses. J Infect Dis. 1987;156:
899-903.
57. Naniche D, Oldstone MB. Generalized immunosuppression: how
viruses underline the immune response. Cell Mol Life Sci. 2000;57:
1399-1407.
58. Tateda K, Ishii Y, Matsumoto T, Yamaguchi K. ‘Break-point Checker-
board Plate’ for screening of appropriate antibiotic combinations
against multidrug-resistant Pseudomonas aeruginosa. Scand J Infect Dis.
2006;38:268-272.
59. Araoka H, Baba M, Takagi S, et al. Monobactam and aminoglycoside
combination therapy against metallo-beta-lactamase-producing
multidrug-resistant Pseudomonas aeruginosa screened using
a ‘break-point checkerboard plate’. Scand J Infect Dis. 2010;42:231-233.
60. Aoki N, Tateda K, Kikuchi Y, et al. Efﬁcacy of colistin combination
therapy in a mouse model of pneumonia caused by multidrug-resistant
Pseudomonas aeruginosa. J Antimicrob Chemother. 2009;63:534-542.
61. Montero M, Horcajada JP, Sorli L, et al. Effectiveness and safety of
colistin for the treatment of multidrug-resistant Pseudomonas aeru-
ginosa infections. Infection. 2009;37:461-465.
62. Marumo K, Komukai D, Hirose M, et al. Evaluation in vitro of the
efﬁcacy of colistin methanesulfonate against bioﬁlm-forming multi-
drug-resistant Pseudomonas aeruginosa (MDRP). J Infect Chemother.
2012; http://dx.doi.org/10.1007/s10156-012-0456-x.
